This company has been acquired
Chembio Diagnostics Future Growth
Future criteria checks 0/6
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 12.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chembio Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2022 | 50 | -23 | -14 | -13 | N/A |
| 9/30/2022 | 60 | -36 | -19 | -17 | N/A |
| 6/30/2022 | 61 | -36 | -21 | -20 | N/A |
| 3/31/2022 | 58 | -38 | -29 | -28 | N/A |
| 12/31/2021 | 48 | -34 | -33 | -31 | N/A |
| 9/30/2021 | 37 | -27 | -31 | -29 | N/A |
| 6/30/2021 | 36 | -26 | -30 | -27 | N/A |
| 3/31/2021 | 34 | -25 | -25 | -20 | N/A |
| 12/31/2020 | 32 | -26 | -23 | -19 | N/A |
| 9/30/2020 | 29 | -22 | -21 | -17 | N/A |
| 6/30/2020 | 28 | -21 | -14 | -9 | N/A |
| 3/31/2020 | 33 | -16 | -14 | -10 | N/A |
| 12/31/2019 | 34 | -14 | -13 | -9 | N/A |
| 9/30/2019 | 35 | -13 | -15 | -11 | N/A |
| 6/30/2019 | 37 | -11 | -16 | -14 | N/A |
| 3/31/2019 | 35 | -10 | -16 | -14 | N/A |
| 12/31/2018 | 35 | -8 | -13 | -12 | N/A |
| 9/30/2018 | 33 | -7 | -6 | -5 | N/A |
| 6/30/2018 | 30 | -5 | -5 | -5 | N/A |
| 3/31/2018 | 25 | -5 | -4 | -3 | N/A |
| 12/31/2017 | 24 | -6 | -6 | -5 | N/A |
| 9/30/2017 | 22 | -7 | -9 | -8 | N/A |
| 6/30/2017 | 18 | -8 | -9 | -8 | N/A |
| 3/31/2017 | 18 | -15 | -8 | -8 | N/A |
| 12/31/2016 | 18 | -13 | -7 | -7 | N/A |
| 9/30/2016 | 18 | -11 | N/A | -1 | N/A |
| 6/30/2016 | 21 | -10 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CEMI's forecast earnings growth is above the savings rate (2.1%).
Earnings vs Market: Insufficient data to determine if CEMI's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CEMI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CEMI's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CEMI's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 02:20 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chembio Diagnostics, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Raymond Myers | Benchmark Company |
| Mark Massaro | Canaccord Genuity |